The FDA requires labeling changes to the prescribing information for Pfizer and GSK RSV vaccines to include warnings about the risk for GBS.
In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 could turn out.
1d
The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...
The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...
The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...
The FDA has mandated updated safety labeling for two respiratory syncytial virus vaccines, Pfizer's Abrysvo and GlaxoSmithKline's Arexvy, following the identification of an increased risk of ...
The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...
Abrysvo lowered the risk of severe lower respiratory illness in newborns 84.7% in the first 90 days of life, and 69.4% in the ...
The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback